司太立(603520.SH):擬4086萬元參與競拍台州仙居一宗商服用地
格隆匯2月16日丨司太立(603520.SH)公佈,公司為滿足公司總部大樓用地的需求,公司擬使用自有資金人民幣4086萬元以參與競拍方式在浙江省台州市仙居縣購得商服用地12,732平方米(19.098畝)。
地塊名稱:福應街道月塘社區永安公園北側地塊;土地位置:福應街道月塘社區永安公園北側;土地面積:12,732平方米(19.098畝,最終以成交確定面積為準);規劃用途:商服用地(旅館用地、商務金融用地);出讓年限:40年。
公司該次擬購買土地使用權,主要是作為公司後續員工宿舍、辦公大樓用地,為公司運營提供必要的保障,有利於公司提升企業形象、吸引人才落地、提升收入水平以及企業發展規模。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.